Sodium phenylacetate/sodium benzoate: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug pregnan...") |
ClaireLewis (talk | contribs) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
*Type: | *Type: | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: | *Routes of Administration: IV | ||
*Common Trade Names: | *Common Trade Names: Ammunol | ||
==Adult Dosing== | ==Adult Dosing== | ||
*5.5g/m2 over 90-120min | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===[[Inborn errors of metabolism|Hyperammonemia]]=== | |||
*<20kg: 250mg/kg in D10 over 90min; then 250mg/kg/d infusion | |||
*>20kg: 5.5g/m2 over 90-120min | |||
==Special Populations== | ==Special Populations== | ||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | ===[[Drug pregnancy categories|Pregnancy Rating]]=== | ||
* | *Pregnancy Category C | ||
===Lactation risk=== | ===Lactation risk=== | ||
* | *Unknown risk | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult: Monitor closely | ||
*Pediatric: | *Pediatric: Monitor closely | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*Adult: | *Adult: caution with use | ||
*Pediatric: | *Pediatric: caution with use | ||
==Contraindications== | ==Contraindications== | ||
| Line 31: | Line 33: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Hypokalemia | |||
*Fluid overload | |||
*Tissue damage with extravasation from peripheral IV | |||
*Neurotoxicity, seizure, coma | |||
*Hyperventilation with metabolic acidosis (similar to salicylate toxicity) | |||
===Common=== | ===Common=== | ||
*Vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment. | |||
==Pharmacology== | ==Pharmacology== | ||
| Line 48: | Line 54: | ||
==See Also== | ==See Also== | ||
*[[Inborn errors of metabolism]] | |||
==References== | ==References== | ||
| Line 54: | Line 60: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Pediatrics]] | |||
Latest revision as of 22:24, 23 September 2019
Administration
- Type:
- Dosage Forms:
- Routes of Administration: IV
- Common Trade Names: Ammunol
Adult Dosing
- 5.5g/m2 over 90-120min
Pediatric Dosing
Hyperammonemia
- <20kg: 250mg/kg in D10 over 90min; then 250mg/kg/d infusion
- >20kg: 5.5g/m2 over 90-120min
Special Populations
Pregnancy Rating
- Pregnancy Category C
Lactation risk
- Unknown risk
Renal Dosing
- Adult: Monitor closely
- Pediatric: Monitor closely
Hepatic Dosing
- Adult: caution with use
- Pediatric: caution with use
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Hypokalemia
- Fluid overload
- Tissue damage with extravasation from peripheral IV
- Neurotoxicity, seizure, coma
- Hyperventilation with metabolic acidosis (similar to salicylate toxicity)
Common
- Vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment.
Pharmacology
- Half-life:
- Metabolism:
- Excretion: